Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCgp100 vs Investigator’s Choice in Previously Untreated Advanced Uveal Melanoma
2024-517290-24-00Phase 2Completed
- Sponsor
- Immunocore
- Start
- Dec 2017
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of tebentafusp in intraocular melanoma (2 arms), sponsored by Immunocore. Primary endpoint: Overall survival. Started Dec 2017; status: completed.
02
Drugs
tebentafusp
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2024-517290-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517290-24-00.